Ponazuril

Ponazuril
Clinical data

Trade names	Marquis
AHFS/Drugs.com	FDA Professional Drug Information
Routes of administration	Oral
ATCvet code	QP51AJ04 (WHO)
Legal status
Legal status	US: ℞-only Veterinary use only
Identifiers
IUPAC name 1-Methyl-3-[3-methyl-4-[4-(trifluoromethylsulfonyl)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione
CAS Number	69004-04-2^Y
PubChem CID	3050408
ChemSpider	2312474^N
UNII	JPW84AS66U
ECHA InfoCard	100.157.907
Chemical and physical data
Formula	C₁₈H₁₄F₃N₃O₆S
Molar mass	457.380 g/mol
3D model (Jmol)	Interactive image
SMILES CC1=C(C=CC(=C1)N2C(=O)NC(=O)N(C2=O)C)OC3=CC=C(C=C3)S(=O)(=O)C(F)(F)F
InChI InChI=1S/C18H14F3N3O6S/c1-10-9-11(24-16(26)22-15(25)23(2)17(24)27)3-8-14(10)30-12-4-6-13(7-5-12)31(28,29)18(19,20)21/h3-9H,1-2H3,(H,22,25,26)^N Key:VBUNOIXRZNJNAD-UHFFFAOYSA-N^N
^NY (what is this?)

Ponazuril (INN), sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of equine protozoal myeloencephalitis (EPM) in horses, caused by Sarcocystis neurona. More recently, veterinarians have been preparing a formulary version of the medication for use in small animals such as cats, dogs, and rabbits against coccidia, an intestinal parasite. Coccidia treatment is far shorter than treatment for EPM.

...
Wikipedia